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An IL1RL1 genetic variant lowers soluble ST2 levels
and the risk effects of APOE-ε4 in female patients
with Alzheimer’s disease
Yuanbing Jiang 1,2 ✉, Xiaopu Zhou1,2,3 ✉, Hiu Yi Wong1,2 ✉, Li Ouyang1,2 ✉, Fanny C. F. Ip1,2,3 ✉,
Vicky M. N. Chau1,2 ✉, Shun-Fat Lau1,2 ✉, Wei Wu 1,2 ✉, Daniel Y. K. Wong1,2 ✉, Heukjin Seo 1 ✉,
Wing-Yu Fu1,2 ✉, Nicole C. H. Lai1,2 ✉, Yuewen Chen1,3,4 ✉, Yu Chen1,3,4 ✉, Estella P. S. Tong1,2 ✉,
Alzheimer’s Disease Neuroimaging Initiative*, Vincent C. T. Mok 5 ✉, Timothy C. Y. Kwok 6 ✉,
Kin Y. Mok1,2,7,8 ✉, Maryam Shoai7,8 ✉, Benoit Lehallier9,89 ✉, Patricia Morán Losada9,10 ✉,
Eleanor O’Brien 11,12 ✉, Tenielle Porter11,12,13 ✉, Simon M. Laws 11,12,13 ✉, John Hardy2,7,8,14 ✉,
Tony Wyss-Coray 2,9,10,15 ✉, Colin L. Masters16 ✉, Amy K. Y. Fu1,2,3 ✉ and Nancy Y. Ip 1,2,3 ✉
Changes in the levels of circulating proteins are associated with Alzheimer’s disease (AD), whereas their pathogenic roles in AD
are unclear. Here, we identified soluble ST2 (sST2), a decoy receptor of interleukin-33–ST2 signaling, as a new disease-causing
factor in AD. Increased circulating sST2 level is associated with more severe pathological changes in female individuals with
AD. Genome-wide association analysis and CRISPR–Cas9 genome editing identified rs1921622, a genetic variant in an enhancer
element of IL1RL1, which downregulates gene and protein levels of sST2. Mendelian randomization analysis using genetic variants, including rs1921622, demonstrated that decreased sST2 levels lower AD risk and related endophenotypes in females carrying the Apolipoprotein E (APOE)-ε4 genotype; the association is stronger in Chinese than in European-descent populations.
Human and mouse transcriptome and immunohistochemical studies showed that rs1921622/sST2 regulates amyloid-beta (Aβ)
pathology through the modulation of microglial activation and Aβ clearance. These findings demonstrate how sST2 level is
modulated by a genetic variation and plays a disease-causing role in females with AD.

A

D is the most common neurodegenerative disease and a
leading cause of mortality in older people1. Its pathological hallmarks include the extracellular accumulation of
Aβ peptides, which form Aβ plaques, and intracellular neurofibrillary tangles composed of hyperphosphorylated tau protein
(P-tau)2. While the pathophysiological mechanisms underlying
AD remain unclear, genome-wide association studies (GWASs)
reveal more than 40 AD-associated genes linked with microglial
functions (for example, APOE, TREM2, BIN1 and CD33), suggesting that microglia play a key role in AD pathogenesis3–5. In
particular, APOE-ε4, the strongest known risk factor for sporadic

AD after chronological age3, affects Aβ accumulation in AD6,7
through regulating the clustering of microglia around Aβ
and the subsequent degradation of Aβ plaques4,8,9. This suggests that microglial dysfunction plays an essential causative
role in AD.
Recent studies show that, besides genetic factors, changes in
secreted proteins in the brain milieu and/or circulatory system
may also disrupt microglial activities and contribute to AD pathogenesis10,11. For example, soluble TREM2 protein (sTREM2) level
is increased in the cerebrospinal fluid (CSF) of individuals with
AD12–14, and injection of sTREM2 in transgenic mouse models of
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amyloidosis alleviates Aβ accumulation by enhancing the interaction between microglia and Aβ and subsequent Aβ phagocytosis15,16. Moreover, the soluble form of a full-length VCAM1 protein
in endothelial cells, sVCAM1, is increased in the plasma and CSF of
individuals with AD17,18; this is suggested to mediate reduced hippocampal neurogenesis and a pro-inflammatory response by microglia during aging19.
Other secreted proteins that contribute to AD pathogenesis
include soluble cytokine receptors comprising the ectodomains
of membrane-bound cytokine receptors, which function as decoy
receptors to attenuate cytokine-mediated signaling20,21. In particular, sST2 is a secreted isoform of the interleukin-33 (IL-33) receptor ST2L (full-length ST2) that is produced by alternative promoter
activation22 (Extended Data Fig. 1). ST2L is expressed by microglia
in the brain23, and activation of IL-33–ST2 signaling decreases Aβ
accumulation via enhanced microglial Aβ-clearance capacity in
transgenic mouse models of amyloidosis24,25. Meanwhile, sST2 acts
as a decoy receptor of IL-33 and inhibits IL-33–ST2 signaling26,27.
Altered sST2 level in plasma is a biomarker of several inflammatory
and cardiac diseases28–31. Notably, recent evidence shows that sST2
levels are also elevated in the blood of individuals with mild cognitive impairment (MCI) or AD24,32. Nonetheless, it is unclear what
regulatory mechanisms underlie sST2 dysregulation and whether
sST2 plays a pathological role in AD.
In the present study, we investigated sST2 regulation in AD
and its roles in disease pathogenesis. We showed that sST2 level
increases in the blood and brains of females with AD and is positively associated with disease progression. Moreover, we identified a
single-nucleotide polymorphism (SNP), rs1921622, in IL1RL1 (the
gene encoding sST2 and ST2L) that is associated with decreased
sST2 expression in human endothelial cells and decreased plasma
and CSF sST2 levels. Mendelian randomization (MR) analysis
showed that, in female APOE-ε4 carriers, decreased sST2 level
results in reduced AD risk and less-severe AD-associated endophenotypes, suggesting a causal effect of sST2 in AD. Subsequent
single-nucleus transcriptomic profiling revealed that the rs1921622
A allele is associated with enhanced microglial activation toward Aβ
and lowered Aβ plaque load in female APOE-ε4 carriers with AD.
Together, our findings suggest that a circulating protein, sST2, in
the brain milieu plays a key role in APOE-ε4-dependent AD pathogenesis in females—by modulating the activation and Aβ-clearance
capacity of microglia—and therefore might be a novel target for
AD therapy.

Results

sST2 is associated with Alzheimer’s disease and its pathological
changes. To investigate how sST2 is involved in AD pathogenesis, we
examined the associations between sST2 level and AD and its related
endophenotypes. We measured the plasma sST2 level of Chinese
individuals with AD (that is, those having Alzheimer’s dementia
with a Montreal Cognitive Assessment (MoCA) score < 21) and
healthy controls (HCs) recruited in Hong Kong (the ‘Chinese_
cohort_1’ hereafter; n = 345 HCs and n = 345 individuals with AD;
Supplementary Table 1). We then performed a linear regression
analysis between plasma sST2 level and AD and its related endophenotypes, adjusting for age, sex, status of cardiovascular diseases
(CVDs; that is, heart disease, hypertension, diabetes mellitus and
hyperlipidemia), body mass index (BMI) and education level, followed by multiple testing correction. The results show that plasma
sST2 level was higher in individuals with AD when compared to
HCs (β (effect size) = 2.072, false discovery rate (FDR) < 0.001;
Fig. 1a). Moreover, plasma sST2 level was positively associated
with the AD-related endophenotypes we examined—namely,
the decreased volumes of gray matter (β = −0.695, FDR = 0.003;
Fig. 1b) and increased levels of plasma biomarkers corresponding
to AD (that is, P-tau181 (ref. 33), β = 0.413, FDR = 0.005; Fig. 1c)
Nature Aging | VOL 2 | JulY 2022 | 616–634 | www.nature.com/nataging
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and neurodegeneration (that is, neurofilament light polypeptide
(NfL)34, β = 0.107, FDR = 0.004; Fig. 1d). Notably, we found a differential regulation of plasma sST2 levels between sexes: while plasma
sST2 level is lower in females than that in males, it exhibits a greater
increase in AD in females (females, β = 2.235, FDR = 6.97 × 10−4;
males, β = 1.926, FDR = 0.148; Extended Data Fig. 2a). In particular, female APOE-ε4 carriers with AD had the greatest increase of
plasma sST2 level compared to that in other subgroups (β = 3.833,
FDR = 0.004; Extended Data Fig. 2b,c and Supplementary Table 2).
Moreover, females showed stronger associations between plasma
sST2 level and AD-related endophenotypes (including gray matter
volumes, plasma P-tau181 levels and plasma NfL levels) than those
in males (Supplementary Table 2). These results suggest that plasma
sST2 level is associated with AD and its related endophenotypes in
a female-specific manner.
We further showed that plasma and CSF sST2 levels are positively correlated within the same individual (R2 = 0.130, P < 0.0001;
n = 107 individuals from the Stanford Alzheimer’s Disease Research
Center (ADRC) cohort35; Fig. 1e). Accordingly, we performed a
linear regression analysis between CSF sST2 level and AD and
Aβ plaque load, adjusting for age, sex and postmortem duration
(PMD), followed by multiple testing correction. Concordant with
the regulation of plasma sST2 level in AD, in the UK Brain Banks
Network (UKBBN) cohort (n = 11 HCs, n = 75 individuals with AD;
Supplementary Data 1), the CSF sST2 level was higher in individuals with AD than in HCs (β = 6.605, FDR < 0.01; Fig. 1f), with a
greater increase in females than that in males (females, β = 7.766,
FDR = 0.034; males, β = 4.019, FDR = 0.241; Extended Data
Fig. 3a). Moreover, CSF sST2 level was positively associated with Aβ
plaque load in the frontal cortex in individuals with AD (β = 0.191,
FDR = 0.031; Fig. 1g,h and Supplementary Fig. 1); this association was also stronger in females than in males (females, β = 0.219,
FDR = 0.041; males, β = 0.026, FDR = 0.787; Extended Data Fig. 3b).
Taken together, these findings suggest that sST2 levels in both the
blood and CSF are increased in AD and associated with disease progression, specifically in female populations.
sST2 level is associated with a genetic variant of IL1RL1. To
understand how sST2 is regulated in AD, we examined the contribution of various factors to the changes of sST2 levels. Specifically,
we examined the associations between plasma/CSF sST2 levels
and sex/age in three independent cohorts including Chinese_
cohort_1, comprising HCs and individuals with AD, and a Japanese
cohort36 and a European-descent cohort (that is, INTERVAL and
LonGenity cohorts37) comprising cognitively normal individuals.
Our results show that plasma sST2 level was lower in females than
in males (β = −3.577, P < 0.001) and, compared to males (Chinese,
R2 = 0.001, P = 0.866; European descent, R2 = 0.010, P = 0.009),
females show a greater association between plasma sST2 level and
age (Chinese, R2 = 0.037, P = 0.002; European descent, R2 = 0.020,
P < 0.001; Extended Data Fig. 4a–c). Furthermore, CSF sST2 level
was associated with both age and sex in the Japanese cohort, and the
association with age, specifically, was greater in females (R2 = 0.152,
P = 0.001) than in males (R2 = 0.044, P = 0.081; Extended Data
Fig. 4d). These data suggest that sST2 level is modulated by age and
sex in both East Asian and European-descent populations. However,
factors such as age and sex accounted for only 6.92% and 13.01% of
the variance of plasma sST2 levels and CSF sST2 levels, respectively
(Extended Data Fig. 4e,f), suggesting that other factors modulate
such differences.
Pilot association studies have identified several genetic variants
in the IL1RL1 gene that are associated with plasma sST2 level38,39,
suggesting that genetic factors contribute to the regulation of sST2
level. Nonetheless, given that these identified SNPs form haplotype
structures in this gene region40, these SNPs might simply be inherited together with the causal variants. Therefore, to identify the key
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genetic modulator(s) of sST2, we used our whole-genome sequencing (WGS) dataset41 of Chinese_cohort_1 to perform a GWAS of
plasma sST2 levels, adjusting for age, sex, AD diagnosis and population structure. Accordingly, we identified 575 genetic variants that
were significantly associated with plasma sST2 level (P < 1 × 10−5)
and found that these variants accounted for 54.86% of the variation
thereof (Fig. 2a and Supplementary Fig. 2a). Among these 575 variants, 79 in or near IL1RL1 that form a haplotype were most strongly
associated with sST2 level (Fig. 2b, Supplementary Fig. 2b and
Supplementary Data 2), and our fine-mapping analysis identified
the sentinel variant rs1921622 (G/A) as the putative causal variant
(with 99.9% probability; Supplementary Fig. 2c and Supplementary
Table 3). In Chinese_cohort_1, the rs1921622 A allele was associated with a 20% decrease in plasma sST2 level in an allele dosedependent manner (β = −3.346, P < 0.001; Fig. 2c). Moreover, CSF
sST2 level was lower in rs1921622 A allele carriers than in noncarriers (UKBBN cohort; β = −2.244, P < 0.05; Fig. 2d). Notably,
rs1921622 alone accounted for 18.04% and 18.29% of the variance
in plasma and CSF sST2 levels, respectively, which is greater than
the contributions of age and sex. Hence, our fine-mapping analysis
using WGS data identified rs1921622 as a key genetic factor that
modulates the plasma and CSF levels of sST2.

cells; Fig. 3b,c). In addition, cell-type-specific association analysis
showed that, compared to noncarriers, rs1921622 A allele carriers had a lower endothelial cell sST2 transcript level (P < 0.01) and
fewer sST2-expressing endothelial cells (P < 0.05; Fig. 3d). These
results collectively indicate that the rs1921622 variant is associated
with decreased sST2 expression in human brain endothelial cells.
To investigate the specific role of rs1921622 in the decreased sST2
expression in endothelial cells, we examined whether rs1921622
and the surrounding genomic region (Fig. 3e) regulate sST2 transcription. Given that noncoding variants commonly modulate gene
expression by functioning as enhancer elements45, we examined
enhancer activity at the rs1921622 locus in the human cerebral
microvascular endothelial cell line (hCMEC/D3). Administration
of the cytokine IL-33 increased the expression and secretion of
sST2 in hCMEC/D3 cells (both P < 0.001; Supplementary Fig. 3a,b).
Moreover, chromatin immunoprecipitation (ChIP) assay showed
that these IL-33-treated hCMEC/D3 cells exhibit increased occupancy of an active enhancer histone mark (that is, acetylated

The rs1921622 locus regulates sST2 in brain endothelial cells.
As rs1921622 is a noncoding variant located in the intronic region
of ST2L, which is downstream of the region encoding sST2, we
examined whether it modulates the expression of sST2 and ST2L.
Association analysis using the Genotype-Tissue Expression (GTEx)
dataset42,43 showed that, compared to noncarriers, rs1921622 A allele
carriers exhibited a lower transcript level of sST2, but not ST2L, in
certain brain regions (for example, hippocampus and frontal cortex;
P < 0.05; Fig. 3a and Supplementary Table 4). Furthermore, an analysis of our previously released human frontal cortex single-nucleus
RNA-sequencing (snRNA-seq) dataset44 revealed that sST2 is exclusively expressed by endothelial cells (that is, CLDN5-expressing
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Fig. 3c). These results suggest that rs1921622 is located at a potential
enhancer element of the sST2 gene.
To demonstrate that the genomic region harboring the
rs1921622 locus contributes to the regulation of sST2 expression,
we deleted this region in hCMEC/D3 cells with a CRISPR–Cas9based approach. We generated two different hCMEC/D3 cell
lines with biallelic 38- or 67-base-pair (bp) deletions (Δ38 bp and
Δ67 bp, respectively) encompassing the rs1921622 locus (Fig. 3e
and Supplementary Fig. 4). Notably, loss of the 38 or 67 bp flanking
the rs1921622 locus decreased the sST2 transcript level in hCMEC/
D3 cells (P < 0.001; Fig. 3g) and concomitantly abolished sST2 protein secretion (P < 0.001; Fig. 3h). These results suggest that the
rs1921622-containing region plays a putative regulatory role as an
enhancer element that regulates sST2 expression in endothelial cells.
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histone H3 Lys27 (H3K27ac)) at the rs1921622 locus, with a concomitant higher level of trimethylated histone H3 Lys4 (H3K4me3)
histone modification (indicating active promoter regions) at the
sST2 promoter region (both P < 0.05; Fig. 3f and Supplementary
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The rs1921622 A allele protects against Alzheimer’s disease in
female APOE-ε4 carriers. Dysregulation of a specific protein
in a disease may indicate that the protein is a causative factor of
the disease, or its altered level may simply be due to tissue damage/reaction. Notably, for a protein that is regulated by genetic
variants, MR analysis examining the associations between the
protein with its genetic modulators and a disease would help illustrate whether the protein has disease-causing effects46. Therefore,
we investigated the causality between sST2 level and AD risk by
examining the associations between the genetic modulators of
sST2 (including rs1921622) and AD risk and its related endophenotypes. Specifically, we performed the two-sample MR analysis of
sST2 on AD risk using eight AD datasets as the discovery cohorts:
the Chinese_cohort_1 dataset, the WGS and array datasets of the
Chinese_cohort_2 (ref. 47) and five public datasets from populations of European descent (that is, the Late Onset Alzheimer’s
Disease (LOAD)48, Alzheimer’s Disease Center 1–3 (ADC1–3)49,50
and Alzheimer’s Disease Neuroimaging Initiative (ADNI) datasets; n = 5,477 HCs, n = 5,910 individuals with AD; Supplementary
Tables 1 and 5). The results show that while sST2 level was not
associated with AD risk in all individuals (Chinese, β = −0.023,
FDR = 0.861; European descent, β = 0.077, FDR = 0.131; Fig. 4a
and Supplementary Table 6), increased sST2 level was associated with increased AD risk in female APOE-ε4 carriers in both
Chinese and European-descent populations (Chinese, β = 0.772,
FDR = 1.70 × 10−5; European-descent, β = 0.168, FDR = 0.023;
Fig. 4a,b and Supplementary Table 6). In particular, among the
genetic modulators of sST2, the top variant, the rs1921622 A
allele, exerted an AD-protective effect in female APOE-ε4 carriers (odds ratio (OR) = 0.757, meta-analysis P value using
Han and Eskin’s random-effects model (RE2 P)51 = 7.78 × 10−5,
FDR = 5.44 × 10−4; Fig. 4c), whereas this effect is absent in the overall population (OR = 0.942, RE2 P = 0.044, FDR = 0.102) or other
subgroups including male APOE-ε4 carriers (OR = 1.086, RE2
P = 0.412, FDR = 0.577), male APOE-ε4 noncarriers (OR = 0.960,
RE2 P = 0.586, FDR = 0.684) and female APOE-ε4 noncarriers
(OR = 0.961, RE2 P = 0.233, FDR = 0.408; Supplementary Tables 7
and 8). Interestingly, both the MR analysis of sST2 and the metaanalysis of rs1921622 showed that the associations between AD
risk and sST2/rs1921622 in female APOE-ε4 carriers are stronger
in the Chinese population than those in the European-descent
populations (Chinese versus European descent, P = 5.55 × 10−4 and
0.017 for the MR analysis of sST2 and meta-analysis of rs1921622,
respectively; Fig. 4a–c and Supplementary Tables 6–8), suggesting
an ethnic-specific effect of sST2/rs1921622 in modulating AD risk.
Next, we examined the effects of the rs1921622 A allele on
the AD-associated endophenotypes in the discovery cohorts.
Consistent with its AD-protective effects (Supplementary Table 9),
the rs1921622 A allele was associated with delayed onset age of
dementia (hazard ratio (HR) = 0.874, FDR = 0.011; Fig. 5a), better
cognitive scores (β = 1.622, FDR = 0.001; Fig. 5b) and larger ento619
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rhinal cortex volumes (β = 0.214, FDR = 0.027; Fig. 5c) in female
APOE-ε4 carriers.
To further confirm the AD-protective effects of the rs1921622
A allele, we examined AD-related endophenotypes in an independent replication cohort: the Australian Imaging, Biomarkers
and Lifestyle cohort (AIBL; n = 190), in which the Aβ deposition
(that is, Aβ+) in the brains of individuals was confirmed by positron emission tomography52. Concordant with our findings from
the discovery cohorts, in female Aβ+ APOE-ε4 carriers, the presence of the rs1921622 A allele was associated with improved cognitive performance as indicated by AIBL Preclinical Alzheimer
Cognitive Composite (AIBLPACC) score and scores related to
cognitive subprocesses including attention processing, episodic
recall and recognition (all FDR < 0.05; Fig. 5d and Extended Data
Fig. 5). Importantly, in a subgroup of female Aβ+ APOE-ε4 carriers whose gray matter volume was traced for 7 years, rs1921622
A allele carriers showed a slower progression of gray matter atrophy (β = −0.027) than that in noncarriers (β = −0.159; FDR < 0.05;
Fig. 5e and Extended Data Fig. 6). Thus, these results validate the
protective effects of the rs1921622 A allele against cognitive decline
and gray matter atrophy among female APOE-ε4 carriers in an
independent Aβ+ cohort.
The rs1921622 A allele is associated with microglial activation
in female APOE-ε4 carriers with Alzheimer’s disease. Given our
findings that the rs1921622 A allele exerts AD-protective effects
in female APOE-ε4 carriers, we subsequently examined whether
this variant modulates Aβ deposition in postmortem human
brains. Among individuals with AD, specifically in females, the
APOE-ε4 carriers exhibited greater Aβ deposition in the frontal
cortex than that in the APOE-ε4 noncarriers (females, β = 1.967,
P < 0.05; males, β = −0.621, P = 0.422; Extended Data Fig. 7a,b).
However, upon further stratification by rs1921622 genotype,
female APOE-ε4 carriers harboring the rs1921622 A allele exhibited less Aβ deposition than those without the allele (β = −2.262,
P < 0.05; Fig. 6a,b and Extended Data Fig. 7c), suggesting that this
allele attenuates the effects of APOE-ε4 on Aβ-related pathological changes in females. Moreover, immunohistochemical analysis
revealed that harboring APOE-ε4 in AD is associated with less
microglial coverage of Aβ plaques (that is, decreased proportion
of Aβ colocalized with Iba-1+ microglia) in females (females,
β = −2.818, P < 0.01; males, β = −0.965, P = 0.327; Extended Data
Fig. 7d,e). In contrast, female APOE-ε4 carriers with AD who coharbored the rs1921622 A allele showed increased colocalization
between Iba-1+ microglia and Aβ plaques (β = 2.017, P < 0.05;
Fig. 6c,d and Extended Data Fig. 7f,g). Thus, these results suggest that in female APOE-ε4 carriers with AD, the rs1921622 A
allele is associated with enhanced microglia–Aβ interaction and
decreased Aβ pathological lesions.
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Next, to investigate the regulatory effects of rs1921622 on
microglial activities at the molecular level, we conducted an association analysis using the microglial snRNA-seq dataset in the frontal
cortices44. We found a negative correlation between the effects of
the rs1921622 A allele and the effects of CSF sST2 level on modulating microglial gene expression in female APOE-ε4 carriers with AD
(R2 = 0.860, P < 0.0001; Extended Data Fig. 8), supporting the notion
that the variant exerts its modulatory effects on microglia through
the regulation of CSF sST2 level. Specifically, we identified 1,639
microglial genes that were associated with rs1921622 genotype:
428 and 1,211 genes were upregulated and downregulated, respectively, in individuals carrying the rs1921622 A allele compared to
noncarriers (FDR < 0.05; Fig. 6e). Gene Ontology (GO) analysis
showed that those upregulated genes are associated with leukocyte migration (FDR = 1.2 × 10−4) and innate immune response
(FDR = 5.4 × 10−3), whereas those with downregulated expression are mainly involved in protein refolding (FDR = 8.1 × 10−3) or
mRNA splicing (FDR = 7.7 × 10−2; Fig. 6f).
Recent studies of microglia in mouse and human brains revealed
a subset of ‘microglial activation genes’, including CD74, APOE
and TREM2, whose expressions are upregulated in AD53,54 and
which are involved in microglial Aβ phagocytosis4,55,56. Therefore,
we investigated whether these genes are associated with rs1921622.
Interestingly, among female APOE-ε4 carriers with AD, the
rs1921622 A allele was associated with increased expression of
these microglial activation genes—specifically, increased transcript levels of CD74, APOE and TREM2 in microglia as well as an
increased proportion of TMEM163+ microglia (Fig. 6g). In contrast,
the rs1921622 A allele was associated with decreased expression
of homeostatic genes including SRGAP2, TMEM119 and P2RY12,
whose expressions commonly indicate a less-reactive microglial
state4,55 (Fig. 6g). Therefore, these results suggest that the rs1921622
A allele promotes the transition of microglia to a more activated
state in female APOE-ε4 carriers with AD.
sST2 treatment impairs microglial Aβ-clearance capacity in
female mouse brains. Our genetic analyses showed that sST2 and its
genetic modulators modulate AD risk and related pathologies possibly by regulating microglial activation and Aβ clearance. To verify
the pathogenic roles of sST2 in AD, we examined the effect of sST2
injection on Aβ-associated pathological changes in an amyloidosis
transgenic 5XFAD mouse model (Fig. 7a). Intracerebroventricular
administration of mouse sST2 to 3-month-old 5XFAD mice for 28 d
increased the Aβ plaque burden in the cortical regions of female
(P < 0.05; Fig. 7b,c) but not male transgenic mice (Extended Data
Fig. 9). In particular, the quantities of both the filamentous form
(that is, X-34+ diffuse fibrils without a dense core57) and the compact
form (that is, X-34+ dense cores with 4G8 halos) of Aβ plaques were
increased in sST2-treated female 5XFAD mice (P < 0.05; Fig. 7d,e

Fig. 3 | Target deletion at rs1921622 decreases soluble ST2 expression and secretion in brain endothelial cells. a, Effects of rs1921622 on sST2 transcript
levels in human tissues. Boxes and lines indicate the effect size and 95% CIs of the rs1921622 A allele for each tissue, respectively (Supplementary
Table 4). Red and blue indicate significant (P < 0.05) and nonsignificant (P ≥ 0.05) associations, respectively. Linear regression test, adjusted for age,
sex, RNA integrity and population structure. b–d, snRNA-seq analysis revealed an association between rs1921622 and sST2 transcript level in brain
endothelial cells. b, Uniform manifold approximation and projection (UMAP) plot showing cell types in the human frontal cortex (n = 169,496 cells from
21 individuals; UKBBN cohort). Excit, excitatory neurons; Inhibit, inhibitory neurons; Astro, astrocytes; Mic, microglia; Endo, endothelial cells; Oligo,
oligodendrocytes; OPCs, oligodendrocyte progenitor cells. c,d, Expression profiles (c) and dot plots (d) of sST2 and CLDN5 transcripts in the endothelial
cells, stratified by rs1921622 genotype. Norm. exp., normalized expression. e, CRISPR–Cas9 genome-editing strategy and locations of the two single-guide
RNA (sgRNA) pairs for 67-bp deletion (Δ67 bp) and 38-bp deletion (Δ38 bp) targeting the rs1921622-harboring region (red). f, H3K27ac analysis of the
rs1921622 locus in hCMEC/D3 cells after IL-33 administration for 24 h (n = 3 per group). T = 4.593, P = 1.01 × 10−2. g,h, Deletion of the rs1921622 locus
decreases transcript level and protein secretion of sST2 in hCMEC/D3 cells. g, sST2 transcript levels (n = 6, 8 and 10 clones for isogenic control, Δ38 bp
and Δ67 bp, respectively). For Δ38 bp versus control, T = − 5.444, P = 1.00 × 10−4; Δ67 bp versus control, T = − 7.612, P < 1.00 × 10−4. h, Levels of sST2
protein in conditioned medium (CM; n = 3, 3 and 4 clones for isogenic control, Δ38 bp and Δ67 bp, respectively). For Δ38 bp versus control: T = −13.450,
P = 2.00 × 10−4; Δ67 bp versus control: T = −16.030, P < 1.00 × 10−4. Data in bar charts are the mean + s.e.m. Statistical tests for f–h were performed as
two-sided unpaired Student’s t-tests. *P < 0.05, **P < 0.01, ***P < 0.001.
620

Nature Aging | VOL 2 | JulY 2022 | 616–634 | www.nature.com/nataging

Articles

NATuRE AGInG

increased the total number of microglia, the clustering of microglia around Aβ plaques, and the number of proliferating (Ki67+)
microglia in the cortical regions (all P < 0.05; Supplementary Fig. 6),
suggesting that sST2 treatment promotes the proliferation of
microglia in the brain. However, compared to the vehicle-injected

and Supplementary Fig. 5). However, sST2 administration did not
affect the burden of less-toxic inert Aβ plaques (that is, X-34+ dense
cores without 4G8 labeling) or the total number of Aβ plaques.
Next, we examined how sST2 regulates the interactions between
microglia and Aβ plaques. In female 5XFAD mice, sST2 injection
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Fig. 4 | The rs1921622 A allele is associated with decreased Alzheimer’s disease risk in female APOE-ε4 carriers. a, Two-sample MR analysis showing
the effects of sST2 levels on AD risk in Chinese (circle) and European-descent (box) populations. Circles/boxes and lines indicate the effect sizes of sST2
and 95% CIs in each subgroup, respectively (Supplementary Table 6). Red and blue indicate significant (FDR < 0.05) and nonsignificant (FDR ≥ 0.05)
associations, respectively. All, overall population; M, male; F, female; ε4+, APOE-ε4 carriers; ε4−, APOE-ε4 noncarriers. b, Two-sample MR analysis showing
the associations between sST2 level and AD risk in female APOE-ε4 carriers in Chinese and European-descent populations. Circles and lines indicate the
effect sizes and standard errors of each SNP, respectively. c, Forest plot showing the meta-analysis results of the rs1921622 A allele on AD risk in female
APOE-ε4 carriers (n = 912 HCs, n = 1,898 individuals with AD). Rectangles and diamonds denote the effect sizes (log OR) obtained from independent
datasets and meta-analysis, respectively. For the independent datasets, horizontal lines indicate 95% CIs, and rectangle size is proportional to the weight
used in the meta-analysis. RE2 P, meta-analysis P value using Han and Eskin’s random-effects model. *FDR < 0.05, **FDR < 0.01, ***FDR < 0.001.

condition, the cortical regions in sST2-injected female 5XFAD
mice showed reduced microglial coverage of Aβ plaques (Fig. 7f,g,
Supplementary Fig. 7 and Supplementary Video 1), suggesting that
sST2 injection inhibits the microglial barrier formation around
Aβ plaques. To verify the inhibitory effects of sST2 on microglial
Aβ clearance, flow cytometry analysis showed that sST2 administration decreases the Aβ-phagocytic capacity of microglia as
indicated by a decrease in the percentage of Aβ+ microglia (that
is, 23.57% methoxy-X04+CD11b+ microglia in the sST2-treated
group versus 32.79% in the control group; P < 0.01; Fig. 7h,i and
Supplementary Fig. 8) and an 11.3–17.0% decrease in Aβ uptake by
microglia (P < 0.05; Extended Data Fig. 10). Together, these findings demonstrate that increased brain sST2 level impairs microglial
Aβ-clearance capacity and exacerbates Aβ accumulation in female
transgenic mice, suggesting its pathogenic roles in female AD.

Discussion

Here, we report that an endothelial cell-secreted protein, sST2, is
upregulated in female individuals with AD. Meanwhile, endothelial
expression of sST2 can be downregulated by the rs1921622 A allele,
a genetic variant that exerts an AD-protective effect specifically
in female APOE-ε4 carriers, a subgroup of people accounting for
24.3–33.6% and 32.5–50.4% of individuals with AD in Chinese and
European-descent populations, respectively (Supplementary Tables
1 and 5). This variant is also associated with enhanced microglial activation, increased microglia–Aβ plaque interaction and
622

decreased Aβ deposition. Taken together, we demonstrate that sST2
regulates microglial activities and that changes in sST2 levels in the
brain milieu impair microglial Aβ-clearance capacity, thus modulating AD risk and its pathological changes.
As sST2 only comprises the extracellular domain of the functional receptor ST2L and is independently transcribed22, it is a
decoy receptor for IL-33–ST2 signaling. ST2L expression is mainly
found in microglia in the brains of both humans and mice58–60, and
IL-33–ST2 signaling regulates microglial activities in tissue repair,
Aβ clearance and synapse engulfment24,25,61,62. The expression profile of sST2 differs between humans and mice: in humans, sST2 is
expressed by brain and peripheral endothelial cells63–65 and monocytes/macrophages60,66, mast cells67 and T cells68 in peripheral systems; while in mice, sST2 is expressed by microglia in the brain59
and fibroblasts69, mast cells67 and T cells68 in peripheral systems.
However, given that sST2 is a secreted protein in the circulatory
system24,70, increased sST2 level likely impacts microglial functions
and AD-related pathological changes in both humans and mice by
blocking the binding of IL-33 to ST2L on microglia. In this study,
sST2 treatment perturbed the interaction between microglia and
Aβ as well as the subsequent Aβ phagocytosis in a mouse model
of amyloidosis (Fig. 7). This finding is consistent with our previous observation that in these mice, IL-33 administration activates
IL-33–ST2 signaling and initiates microglial chemotaxis toward Aβ
plaques, subsequently enhancing Aβ phagocytosis24,25. Further corroborating the pathological role of sST2 in microglia in AD, among
Nature Aging | VOL 2 | JulY 2022 | 616–634 | www.nature.com/nataging
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Fig. 5 | The rs1921622 A allele is associated with changes of Alzheimer’s disease-related endophenotypes in female APOE-ε4 carriers. a, Cumulative
dementia-free probability in female APOE-ε4 carriers with AD stratified by rs1921622 genotype (n = 314, 568 and 300 G/G, G/A and A/A carriers,
respectively; LOAD and ADC1–3 cohorts). Cox regression test, adjusted for population structure, with multiple testing correction. b, Individual MiniMental State Exam (MMSE) scores of female APOE-ε4 carriers with AD stratified by rs1921622 genotype (n = 131, 158 and 61 G/G, G/A and A/A carriers,
respectively; Chinese_cohort_2). Linear regression test, adjusted for age and population structure, with multiple testing correction. β = 1.622. c, Effect size
of the rs1921622 A allele on brain region volume in female APOE-ε4 carriers with cognitive impairment (n = 38, 86 and 57 G/G, G/A and A/A carriers,
respectively; ADNI cohort). Linear regression test, adjusted for age, ICV, magnetic resonance imaging (MRI) platforms, dementia stages and population
structure, with multiple testing correction. Data are presented as effect sizes (boxes) and 95% CIs (lines). Red and blue indicate significant (FDR < 0.05)
and nonsignificant (FDR ≥ 0.05) associations, respectively. Fusiform, fusiform gyrus; MidTemp, middle temporal gyrus. d, Individual cognitive scores in
female Aβ+ APOE-ε4 carriers stratified by rs1921622 genotype (n = 59 G carriers (G/−), n = 29 A/A carriers; AIBL cohort). Wilcoxon rank-sum test, with
multiple testing correction. W = 1087.0, 1115.5, 1083.0 and 916.5 for AIBLPACC, attention processing, episodic recall and recognition scores, respectively.
e, Longitudinal gray matter volume in female Aβ+ APOE-ε4 carriers stratified by rs1921622 genotype (n = 50 and 19 data points from 12 G carriers (G/−)
and 5 A/A carriers, respectively; AIBL cohort). Linear mixed model test; adjusted for baseline age and MRI scanners, with multiple testing correction.
β = −0.159 (G/−) and −0.027 (A/A); F = 8.804. Data in box-and-whisker plots are presented with maximum, 75th percentile, median, 25th percentile
and minimum values; plus signs denote mean values; data in regression lines are presented as the slope (red/blue) and 95% CIs (gray). *FDR < 0.05,
**FDR < 0.01, ***FDR < 0.001. a.u., arbitrary units.

female APOE-ε4 carriers with AD, those carrying the rs1921622 A
allele (who have lower sST2 levels) exhibit enhanced microglia–Aβ
plaque interactions and a smaller Aβ plaque area than noncarriers.
Thus, perturbation of endogenous IL-33–ST2 signaling by sST2
may lead to impaired microglial chemotaxis, Aβ uptake and barrier
formation, which subsequently contribute to AD pathogenesis.
What are the regulatory mechanisms of sST2? In mice, sST2
expression is regulated by a proximal promoter located upstream
of the 5′ untranslated region of sST2, which is increased by oncogenes, serum and other mitogenic stimuli69. While the regulatory
mechanisms of sST2 expression might be different between humans
and mice, sST2 regulation in humans remains largely unknown.
Our analyses in Chinese and European-descent populations corroborate findings from previous studies that sST2 levels in humans
are associated with age, sex and genetic variants37,38, and reveal that
genetic components play a dominant role in the regulation of sST2
levels, accounting for 54.86% of the variance of these levels. In particular, our GWAS and fine-mapping analyses identified rs1921622
as a putative causal variant associated with sST2 (causal probability
of 99.99%), and our ChIP assay and CRISPR–Cas9 genome editing verified that the rs1921622-containing region is an enhancer
Nature Aging | VOL 2 | JulY 2022 | 616–634 | www.nature.com/nataging

element that regulates the sST2 gene in endothelial cells. Thus, as
rs1921622 is a key genetic modulator of sST2, future investigations
of the epigenetic events at the rs1921622 locus may help elucidate
the regulatory mechanisms of sST2.
Single-nucleus transcriptomic profiling of postmortem human
brains shows that sST2 is mainly expressed in brain endothelial cells (Fig. 3). Dysregulation of sST2 in the brain exacerbates
AD-associated pathological changes, specifically by impairing the
phagocytic capacity of microglia. Thus, we demonstrate a new pathogenic role of the brain vasculature in AD that regulates microglial
activities via sST2. Indeed, apart from Aβ and tau-related pathological changes, neurovascular dysfunction occurs early in AD and is
implicated in its pathogenesis71. While the exact pathological functions of this brain vasculature remain unclear, vasculature-secreted
cytokines (for example, CXCL1) in the peripheral system regulate
the activation and migration of immune cells, thereby mediating
the immune response in tissues72. Similarly, emerging studies suggest that the brain vasculature serves as a critical source of soluble
inflammatory proteins such as IL-1β, IL-6, IL-8, tumor necrosis factor, transforming growth factor and monocyte chemoattractant protein-1 (refs. 73,74). Therefore, besides sST2, other soluble factor-based
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Fig. 6 | The rs1921622 A allele enhances microglial activities toward Aβ in female APOE-ε4 carriers with Alzheimer’s disease. a,b, Representative images
(a) and quantification (b) showing Aβ plaque area in the frontal cortices of females with AD stratified by APOE-ε4 and rs1921622 genotypes (n = 4 G/G
carriers and 15 A carriers (A/−) among APOE-ε4 noncarriers (non-ε4); n = 5 G/G carriers and 18 A/− carriers among APOE-ε4 carriers (ε4); UKBBN
cohort). Test for effects of APOE-ε4: β = 3.448 (G/G) and 1.549 (A/−), P = 4.83 × 10−2 (G/G) and 2.54 × 10−1 (A/−); test for effects of rs1921622, β = 0.288
(non-ε4) and −2.262 (ε4), P = 7.02 × 10−1 (non-ε4) and 3.71 × 10−2 (ε4). Scale bar, 200 μm. c,d, Representative images (c) and quantification (d) showing
colocalization between Aβ plaques (brown) and Iba-1+ microglia (purple) in the frontal cortices of female APOE-ε4 carriers with AD stratified by rs1921622
genotype (n = 5 G/G carriers, n = 18 A/− carriers; UKBBN cohort). β = 2.017, P = 2.53 × 10−2. Scale bar, 100 μm. e, Volcano plot showing the associations
between rs1921622 and microglial genes in the frontal cortices of female APOE-ε4 carriers with AD (n = 2,636 microglia of eight individuals; UKBBN
cohort). Blue and red dots indicate microglial genes that were negatively and positively associated with the rs1921622 A allele, respectively. Dot size is
proportional to FDR (log10 scale). The top five negatively and positively associated genes are labeled. f, Representative GO terms enriched in the rs1921622associated microglial genes. Blue and red indicate GO terms enriched for the downregulated and upregulated genes, respectively, in rs1921622 A allele
carriers. g, Dot plot showing the expression levels of microglial activation genes and homeostatic genes stratified by rs1921622 genotype. Data in box-andwhisker plots are presented with maximum, 75th percentile, median, 25th percentile and minimum values; plus signs denote mean values. Statistical tests
were performed by linear regression analysis, adjusted for age and PMD. *P < 0.05, **P < 0.01, ***P < 0.001; #P < 0.05, ##P < 0.01, ###P < 0.001.
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Fig. 7 | Increased brain soluble ST2 levels exacerbate Aβ accumulation and impair microglial Aβ clearance in female 5XFAD mice.
a, Intracerebroventricular (i.c.v.) delivery of sST2 to 3-month-old 5XFAD mice. b–e, Aβ deposition in the cortices of 4-month-old female 5XFAD mice after
i.c.v. delivery of sST2-Fc or Fc as a control. b,c, Representative images (b) and quantification (c) of Aβ plaques (percentage of total cortical area; control
n = 6 mice, sST2 n = 7 mice). T = 2.758, P = 1.86 × 10−2. Scale bar, 1 mm. d, Confocal images of X-34-stained (blue) and 4G8-labeled (red) Aβ. Filamentous
(filled arrowheads) and compact (hollow arrowheads) Aβ plaques. Scale bar, 100 μm. e, Quantification of filamentous, compact, inert and total Aβ plaques
(control n = 6 mice, sST2 n = 7 mice). T = 3.235, 2.274, −0.770 and 1.050, respectively; P = 7.95 × 10−3, 4.40 × 10−2, 4.57 × 10−1 and 3.16 × 10−1, respectively.
f, Merged confocal z-stack images with orthogonal X–Z and Y–Z views showing co-staining of 4G8-labeled Aβ plaques (white) and Iba-1+ microglia
(green; red arrowheads indicate microglial soma) in the cortices of 4-month-old female 5XFAD mice after i.c.v. delivery of sST2-Fc or Fc as a control
(single-channel images in Supplementary Fig. 7). Scale bar, 10 μm. g, Quantification of microglial coverage of Aβ plaques (control n = 6 mice, sST2 n = 7
mice). T = −2.298, P = 4.22 × 10−2. h,i, Microglial Aβ uptake activity in the cortices of 4-month-old female 5XFAD mice after i.c.v. delivery of sST2-Fc or
Fc as a control. Representative scatterplots (h) and quantification (i) show the percentages of CD11b+ cells containing methoxy-X04-labeled Aβ (control
n = 7 mice, sST2 n = 7 mice; gating strategy in Supplementary Fig. 8). T = −3.620, P = 3.50 × 10−3. The scatterplots of wild-type (WT) mice in h were used
to gate methoxy-X04+ microglia (that is, MeX04+CD11b+ cells). Data in bar charts are the mean + s.e.m. Statistical tests were performed as two-sided
unpaired Student’s t-tests. *P < 0.05, **P < 0.01, ***P < 0.001.
Nature Aging | VOL 2 | JulY 2022 | 616–634 | www.nature.com/nataging

625

Articles
cross-talk between the vasculature and other cell types likely occurs
in the brain. Accordingly, identifying the proteins involved in this
cross-talk may provide insights into novel pathological mechanisms
of AD.
We show that sST2 plays a disease-causing role in AD in a
female-specific manner. Indeed, emerging evidence suggests that
sex is an important factor that underlies the heterogeneity of AD;75
compared to males, females are more likely to develop AD76 and
experience faster cognitive decline after an MCI or AD diagnosis76,77. Given that sST2 inhibits IL-33–ST2 signaling and microglial activities, this sex-specific causal effect of sST2 in AD may be
attributed to the differential regulation of IL-33–ST2 signaling and
differential microglial activities between sexes. Concordant with
previous studies78, we show that microglia in female individuals
with AD, particularly those who carry APOE-ε4, have significantly
lower Aβ phagocytic capacity when compared to male individuals
(Extended Data Fig. 7). Meanwhile, compared to males, females
show a greater increase of sST2 upon AD development. Hence, it
would be interesting to examine whether increased sST2 level in
female brains exhibits a stronger inhibitory effect on microglial
activities and impairs their Aβ-clearance capacity. Moreover, sex
hormones (for example, testosterone) regulate IL-33 expression in
mast cells, maintaining a higher activity of IL-33–ST2 signaling in
men79, which might protect men from being affected by increased
sST2 levels. Together, increased sST2 levels, resulting from aging or
the absence of the rs1921622 A allele, might have more detrimental
impacts in microglial activities and functions in females, eventually
leading to a greater risk of AD. Therefore, investigating the underlying mechanisms of this female-specific, disease-causing role of
sST2 may be key to understanding the differential progression of
AD between sexes.
In addition to its female-specific effects, our genetic analyses
demonstrate that sST2/rs1921622 plays disease-causing effects in
females with AD, specifically those carrying APOE-ε4, suggesting
a potential interaction between IL-33–ST2 signaling and ApoE. In
the brain, ApoE is mainly produced by astrocytes, and its expression is upregulated in microglia in AD53,80. Single-cell RNA-seq of
amyloidosis mouse models revealed that a microglial subpopulation
transitions from a homeostatic state to an activated state termed
‘disease-associated microglia’ or ‘activated response microglia’4,55,
with increased expression of microglial activation genes (including
APOE, AXL, TREM2 and CD74)53–56 that are crucial regulators of
phagocytic processes81–84. In contrast, perturbation of ApoE functions in the brain abolishes the induction of this microglial activation state, resulting in reduced Aβ phagocytic capacity4,55. Thus,
ApoE-mediated microglial activation may protect against AD
and be required for Aβ clearance and brain homeostasis. Notably,
the presence of the rs1921622 A allele modulates the transition
of microglia from a homeostatic state to a more activated state in
female APOE-ε4 carriers with AD, characterized by the increased
expression of the aforementioned microglial activation genes
(Fig. 6). Therefore, IL-33–ST2 signaling and ApoE might converge
to regulate the expression of these specific genes in microglia,
thereby modulating the activation state and Aβ-clearance capacity
of microglia. Interestingly, in the periphery, IL-33 administration
ameliorates the formation of macrophage foam cells (lipid-laden
macrophages) and the development of atherosclerotic plaques
in the ApoE−/− model of atherosclerosis85. Therefore, it would be
of interest to determine whether the modulation of IL-33–ST2
signaling reduces the detrimental effects of APOE-ε4 on Aβ accumulation through the regulation of lipid metabolism in AD.
Our findings suggest that sST2 is a promising therapeutic target for AD. First, as sST2 is mainly expressed by endothelial cells,
this enables cell-type-specific manipulation of sST2 expression,
and that manipulation may not need to cross the blood–brain barrier. Second, sST2 levels are elevated in individuals with MCI or
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early-stage AD24,32, suggesting the potential applicability of sST2 in
early intervention strategies. Third, the deletion of the rs1921622
locus in a human brain endothelial cell line with high efficacy demonstrates the feasibility of this approach to silence sST2 expression and secretion without disrupting the activities of ST2L; this
is because the epigenetic and transcriptional controls of sST2 are
distinct from those of ST2L86, and the rs1921622 A allele only
modulates sST2 but not ST2L expression. Fourth, given our finding that the rs1921622 A allele is a common AD-associated variant, manipulations of sST2 by targeting this genetic variant could be
developed for specific subgroups of individuals who have high sST2
levels (for example, female individuals who carry APOE-ε4 but not
the rs1921622 A allele, accounting for 6.2–12.2% of individuals with
AD), enabling patient stratification and precision medicine.
Nonetheless, there are some knowledge gaps regarding the functions and regulation of sST2 in AD. First, while MR analysis of
cross-sectional studies shows that sST2 plays a causal role in AD, longitudinal studies investigating the associations between sST2 level
and cognitive decline and/or AD risk in cognitively normal populations would help support the notion that sST2 has disease-causing
effects in AD. Meanwhile, given that such effects are only observed
in female APOE-ε4 carriers, they are likely masked in recent genetic
studies of AD, in both the overall population (P = 0.881)87 and
APOE-ε4 carriers (P = 0.798)88. Therefore, stratification of AD datasets according to sex and APOE-ε4 genotypes may help to better
investigate the disease effects of sST2 or other AD-associated factors. Moreover, as we observed that sST2/rs1921622 has stronger
modulatory effects on AD risks in the Chinese population than in
the European-descent populations, validation of this finding by
future studies using larger datasets would help clarify this potential
ethnic-specific effect of sST2. Lastly, while an increased brain level
of sST2 contributes to AD pathogenesis, given the positive correlation between plasma and CSF sST2 levels, it would be interesting to
examine whether peripheral sST2, produced by peripheral endothelial cells65, monocytes/macrophages60,66, T cells68 and mast cells67, is
blood–brain barrier permeable and plays a pathogenic role in AD.
Indeed, recent studies show that several drugs (for example, sacubitril/valsartan) can reduce peripheral sST2 levels in individuals
with heart failure89. It is of interest to examine whether these drugs
can also regulate peripheral sST2 levels in individuals with AD and
ameliorate the disease-related pathological changes.
In summary, we uncovered an alternative pathogenic mechanism of AD that involves microglial dysfunctions mediated by sST2.
Dysregulation of endothelial cell-secreted sST2 leads to increased
plasma and CSF levels of sST2 and impairs Aβ clearance by microglia, resulting in increased Aβ accumulation in AD. Furthermore, we
identified an AD-protective genetic variant, rs1921622, which downregulates sST2 expression and attenuates the APOE-ε4-related risk
and pathological changes of AD through the regulation of microglial
signaling. Thus, a better understanding of how sST2—a biomarker
and potential drug target for AD—is genetically regulated can aid
the design of AD intervention strategies and clinical trials.

Methods

Recruitment for Chinese_cohort_1. This study was approved by the Joint Chinese
University of Hong Kong–New Territories East Cluster Clinical Research Ethics
Committee at the Prince of Wales Hospital, the Chinese University of Hong
Kong and the Hong Kong University of Science and Technology (HKUST). All
individuals provided written informed consent for both study enrollment and
sample collection. Specifically, we recruited a total of 690 Hong Kong Chinese
individuals ≥ 60 years old, including 345 individuals with AD and 345 HCs, who
visited the Specialist Outpatient Department of the Prince of Wales Hospital
at the Chinese University of Hong Kong from April 2013 to February 2018.
We established a clinical diagnosis of AD based on the American Psychiatric
Association’s Diagnostic and Statistical Manual of Mental Disorders, Fifth
Edition90. All individuals underwent a medical history assessment, clinical
assessment, cognitive and functional assessments using the MoCA test, and
neuroimaging assessment by MRI91,92, and only those with cognitive dysfunctions
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(that is, those having Alzheimer’s dementia with MoCA score < 21) were included
in the AD group in this study. Individuals with any notable neurological disease
besides AD or a psychiatric disorder were excluded. We recorded age, sex, years of
education, medical history and history of CVDs. We prepared DNA and plasma
samples from whole-blood samples and stored them at −80 °C until use. We used
T1-weighted MRI to retrieve brain imaging data from 192 individuals (n = 77
individuals with AD, n = 115 HCs) from the Prince of Wales Hospital. Raw imaging
files were deidentified and processed by AccuBrain IV1.2 (BrainNow Medical
Technology) for the analysis of gray matter volumes.
UK Brain Banks Network dataset. We obtained the following samples of the
Medical Research Council (MRC) UKBBN dataset (Bristol Brain Bank): CSF
samples, frontal cortex sections, frozen frontal cortex tissues and genomic DNA
samples (Supplementary Data 1), from South West Dementia Brain Bank (SWDBB),
which receives approval from North Somerset and South Bristol Research Ethics
Committee to operate as a research tissue bank. For our initial sample selection
from the UKBBN dataset, we excluded individuals with other neurodegenerative
diseases, severe vascular diseases (for example, stroke), an intoxicated state,
infection, prions, severe inflammatory diseases (for example, autoimmune diseases),
structural brain disorders, metabolic/nutritional diseases, trauma, delirium,
genetic disorders (for example, Down syndrome) or other systemic diseases. For
CSF samples, we further selected samples with a PMD ≤ 30 h, yielding a total of
86 individuals (n = 75 individuals with AD, n = 11 HCs). In addition, we obtained
snRNA-seq data from frozen frontal cortical samples from the UKBBN (n = 12
individuals with AD, n = 9 HCs) from our previously published dataset44.
Other cohorts and data for association studies. We obtained the following
data for replication studies: (i) genomic, demographic and clinical data from
Chinese_cohort_2 (ref. 47); (ii) genomic, demographic and clinical data from the
LOAD Family Study48; (iii) genomic, demographic and clinical data from the
National Institute on Aging (NIA) ADC cohorts49,50; (iv) genomic, demographic,
clinical and brain imaging data from the ADNI cohort; (v) genomic, demographic
and transcriptomic data from the GTEx dataset;42,43 (vi) plasma biomarker, CSF
biomarker, demographic and clinical data from the Stanford ADRC cohort;35
(vii) plasma biomarker and demographic data from the INTERVAL and LonGenity
cohorts37 retrieved from the online database (https://twc-stanford.shinyapps.io/
aging_plasma_proteome/); (viii) CSF biomarker and demographic data from a
Japanese cohort;36 and (ix) genomic, demographic, clinical and brain imaging data
from the AIBL cohort52. Details related to sample and data collection are presented
in the Supplementary Notes.
DNA and plasma extraction from human blood samples. We collected wholeblood samples (3 ml) from individuals into K3EDTA tubes (VACUETTE). We
centrifuged the samples at 2,000g for 15 min to separate the cell pellet and plasma.
The plasma was collected, aliquoted and stored at −80 °C until use. We sent the cell
pellets to the Centre for PanorOmic Sciences (Genomics and Bioinformatics Cores,
University of Hong Kong) for genomic DNA extraction using the QIAsymphony
DSP DNA Midi Kit (Qiagen) on a QIAsymphony SP platform (Qiagen). Genomic
DNA was eluted with water or Elution Buffer ATE (Qiagen) and stored at 4 °C. We
determined the DNA concentration by BioDrop µLITE+ (BioDrop).
Measurement of protein levels in human samples and cell lines. We measured
the plasma level of sST2 in 613 individuals from Chinese_cohort_1 (n = 277
individuals with AD, n = 336 HCs); CSF level of sST2 in 86 individuals from the
UKBBN cohort (n = 75 individuals with AD, n = 11 HCs); and the level of sST2
secreted by hCMEC/D3 cells using the Human ST2/IL-33 R Quantikine ELISA
Kit (DST200; R&D Systems). The plasma levels of NfL (n = 154 individuals with
AD, n = 135 HCs) and P-tau181 (n = 156 individuals with AD, n = 134 HCs) in
individuals from Chinese_cohort_1 were measured by the Quanterix Accelerator
Laboratory using the Quanterix NF-light SIMOA Assay Advantage Kit (103186)
and P-Tau 181 Advantage V2 Kit (103714), respectively93.
Whole-genome sequencing and single-nucleotide polymorphism array for
genotyping. We submitted DNA samples from 427 individuals from Chinese_
cohort_1 (n = 233 individuals with AD, n = 194 HCs) to Novogene for library
construction and WGS. The samples were sequenced on the Illumina HiSeq X
platform (average depth: 5×), and individual genotypes were analyzed using the
GotCloud pipeline41. The genotype results, which were stored in VCF files, were
used for principal-component analysis. The top five principal components were
generated by PLINK software (v1.9)94 with the following parameters: --pca header
tabs, --maf 0.05, --hwe 0.00001 and --not-chr x y.
We subjected the rest of the genomic DNA samples, including 263 from
Chinese_cohort_1 (n = 112 individuals with AD, n = 151 HCs) and 113 from the
UKBBN cohort (n = 102 individuals with AD, n = 11 HCs), to SNP array for the
genotyping of chr2: 102966067 (GRCh37/hg19), APOE-ε2 and APOE-ε4 using
TaqMan Assays rs1921622, C___1226146_10, 4351376; rs7412, C___904973_10,
4351376; and rs429358, C___3084793_20, 4351376, respectively (Thermo Fisher
Scientific). We performed real-time quantitative PCR (qPCR) using the 7500 Fast
and QuantStudio 7 Flex Real-Time PCR System (Applied Biosystems). We stored
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the results in EDS files and input them into TaqMan Genotyper Software (Applied
Biosystems) for the joint genotyping of SNPs.
Immunohistochemical staining of postmortem human brain sections. We
obtained formalin-fixed, paraffin-embedded, postmortem, frontal cortex sections
from 78 individuals with AD from the UKBBN cohort. We first deparaffinized
and rehydrated the sections with xylene and graded ethanol solutions. To stain
Aβ, we treated the sections with formic acid at room temperature (RT) for 5 min
and quenched endogenous peroxidase activity with a 3% hydrogen peroxide
solution. We then incubated the sections with a mouse anti-human Aβ antibody
(1:500 dilution; clone NAB228, SC-32277, Santa Cruz Biotechnology) overnight
at 4 °C. After washing, we incubated the sections with horseradish peroxidase
(HRP)-labeled anti-mouse IgG (QD440-XAKE, RTU, BioGenex) and developed
signals with 3,3′-diaminobenzidine (DAB) substrate (QD440-XAKE, BioGenex).
To co-stain microglia and Aβ protein, we performed double immunohistochemical
staining; after deparaffinization and rehydration, the sections were treated with
sodium citrate buffer (10 mM sodium citrate, pH 6.0) for 25 min and blocked,
then endogenous peroxidase activity was quenched by 3% hydrogen peroxide
solution. We then incubated the sections with the mouse anti-human Aβ antibody
(SC-32277) and rabbit anti-human Iba-1 (1:100 dilution; 019-19741, polyclonal,
FUJIFILM Wako Pure Chemical) overnight at 4 °C. After washing, we incubated
the sections with HRP-labeled anti-mouse and AP-labeled anti-rabbit (HK59750K, Double Staining kit, BioGenex) followed by substrate development with DAB
(QD440-XAKE, BioGenex) and Fast Red Substrate (HK182-5KE, BioGenex). We
then counterstained the sections with Mayer’s hematoxylin (HK100-9K, BioGenex)
and mounted them with coverslips. We used Tris-buffered saline with 0.01% Triton
X-100 as the buffer for washing and to dilute primary antibodies. We took images
with a ZEISS Axio Scan.Z1 scanner and processed them with ZEN microscope
software v3.2 (ZEISS).
To quantify Aβ plaques, we took ten random images of each section. After
background subtraction and threshold adjustment, we analyzed the Aβ plaques
using the Analyze Particles function in Fiji (ImageJ v1.53c). We determined the
total Aβ area, number of Aβ plaques and median plaque size for each section.
We calculated Aβ plaque load (percentage area) by dividing the total Aβ area
by the total image area (10 mm2). To quantify microglia–Aβ co-staining, we
selected 20 random images of each section and processed them with the Colour
Deconvolution function to separate the data into three color channels (that is,
DAB, Fast Red and hematoxylin). After adjusting the threshold, we selected
Aβ plaques and microglia using the Create Selection function, then analyzed
them using the Analyze function. We determined the total Aβ area and Aβ area
colocalized with Iba-1 staining. We calculated the Aβ plaque area colocalized with
microglia (percentage total Aβ) by dividing the Aβ area colocalized with Iba-1
staining by the total Aβ area. Two independent researchers performed section
staining, image acquisition and image quantification; they also randomly selected
and quantified images in a blinded manner.
Association analysis and data visualization for the GWAS. We performed the
association analysis between SNPs and plasma sST2 level at the genome-wide
level in Chinese_cohort_1 with PLINK software (v1.9)94, adjusting for age, sex,
AD diagnosis and the top five principal components as covariates (given that they
have relatively larger eigenvalues with higher power in explaining the population
variation in the initially calculated 20 principal components; Supplementary Data
3), using the following parameters: --keep-allele-order, --linear, --ci 0.95, --hwe
0.00001 and --maf 0.05. To visualize the data, we generated a Manhattan plot
and quantile–quantile plot using the manhattan() function and qq() function of
the R qqman package (v0.1.4), respectively. We generated regional plots for the
IL1RL1 locus using LocusZoom. We performed fine-mapping analysis of the
effects of the IL1RL1 locus on plasma sST2 level using CAVIAR software (v2.2)95
and generated association test results and pairwise LD information using PLINK
software (v1.9) with the following parameters: --hwe 0.00001, --maf 0.05, --r,
--matrix, --chr 2, --from-bp 102000000 and --to-bp 104000000. We generated the
fine-mapped regional plot using the plot_ly() function of the R plotly package
(v4.9.1) and plotted LD and haplotype structures using Haploview (v4.2). To
identify all independent sST2-associated variants (r2 < 0.2), we subjected variants
with P < 1 × 10−5 according to the sST2 GWAS to analysis by PLINK software
(v1.9; parameters: --hwe 0.00001, --maf 0.05, --clump-p1 0.00001, --clump-r2 0.2,
--chr 2 and --clump-kb 2000), yielding 29 independent sST2-associated variants
(Supplementary Data 2). We used the calc.relimp() function of the R relaimpo
package (v2.2-3)96,97 to quantify the contributions of genetic factors (that is, the 29
independent sST2-associated variants) and nongenetic factors (that is, age and sex)
to sST2-level variance.
Association analysis of rs1921622 in transcriptome datasets. We used human
tissue sST2 and ST2L transcript levels as well as rs1921622 genotype data from the
GTEx dataset42,43 for the genotype–expression association test, adjusting for age,
sex, RNA integrity (that is, RNA integrity number) and population structure
(that is, the top four principal components). We performed rank-based
normalization of transcript levels using the rntransform() function of the
R GenABEL package (v1.8).
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We obtained the transcript levels of sST2 and ST2L in the human frontal
cortex at the single-cell level by realigning the FASTQ files of our previously
published snRNA-seq dataset44 using a modified reference genome. Specifically,
we separated the IL1RL1 region (chr2: 102,311,563–102,352,037) in the GTF file
of the original GRCh38/hg38 pre-mRNA reference genome into three parts: the
sST2-specific region (chr2: 102,343,416–102,346,100), the ST2L-specific region
(chr2: 102,311,563–102,337,147 and 102,346,101–102,352,037) and the overlapping
region (chr2: 102,337,148–102,343,415). We generated a modified reference
genome with Cell Ranger (v3.0.1) using the new GTF file and original FASTA file.
In the subsequent quality-control step, we performed the quantification of gene
levels and cell-type identification using Seurat (v3.0)44. For the association analysis
between genotype and candidate gene expression in each cell cluster, we performed
a linear regression analysis, adjusting for age, sex, AD diagnosis and PMD. The
level of significance was set at an FDR < 0.05. We performed a GO analysis of
associated genes using DAVID Bioinformatics Resources98,99.
Analysis of the association between rs1921622 and Alzheimer’s disease risk.
We performed a meta-analysis to examine the effects of rs1921622 genotype
on AD risk. Specifically, we determined the effect sizes (that is, log ORs) and
standard errors from eight AD datasets (that is, the Chinese_cohort_1 dataset,
the WGS and array datasets of Chinese_cohort_2 and the LOAD, ADC1, ADC2,
ADC3 and ADNI datasets) using logistic regression with age, sex and the top five
principal components as covariates. We summarized and processed the results
by METASOFT (v2.0.0)51 to estimate the joint risk effects and significance levels
under Han and Eskin’s random-effects model (RE2)51. We further performed
multiple testing correction using the RE2 P values to generate the FDR values. We
then input the results into ForestPMPlot (v1.0.2) to generate forest plots for
data visualization.
Two-sample Mendelian randomization analysis. We performed the two-sample
MR analyses of the associations between sST2 level and AD risk in the overall
population and subgroups of individuals in the Chinese and European-descent
populations using the mr() function and inverse‐variance weighted method of the
R TwoSampleMR package (v0.5.6), followed by multiple testing correction.
Accordingly, for the analysis in European-descent populations, we selected
the cis-regulating (chr2: 102,820,000–103,100,000; GRCh37/hg19) protein
quantitative trait loci (pQTL) for plasma sST2 levels39 for downstream filtering.
Specifically, we used the statistical results from an independent plasma sST2 cisregulating pQTL dataset from European-descent populations38 to filter out the loci
that did not pass the genome-wide threshold (P < 5 × 10−8) or had the opposite
direction of regulating effects in the two datasets. Moreover, we further used the
statistical results from the GTEx dataset42,43 to filter the loci, and only kept the loci
associated with the altered sST2 expression in the expressing tissues (that is, meta
P < 1 × 10−5 in the brain regions and lungs) but not the altered ST2L expression
in the expressing tissues (that is, P > 0.1 in the lungs) for LD clumping by PLINK
software (v1.9) with the following parameters: --maf 0.05, --hwe 0.00001,
--clump-p1 0.00000005, --clump-r2 0.2 and --clump-kb 2000. We obtained a total
of seven independent instrumental variables (rs1921622, rs13001325, rs4851575,
rs10515922, rs11123935, rs10200945 and rs951774), then generated their effects on
AD risk by the meta-analysis in European-descent populations using the LOAD,
ADC1, ADC2, ADC3 and ADNI datasets.
For the analysis in Chinese populations, we subjected the cis-regulating (chr2:
102,820,000–103,100,000; GRCh37/hg19) pQTL for plasma sST2 levels in the
Chinese_cohort_1 (WGS) dataset to LD clumping by PLINK software (v1.9)
with the following parameters: --maf 0.05, --hwe 0.00001, --clump-p1 0.00001,
--clump-r2 0.5 and --clump-kb 2000. We obtained a total of seven independent
instrumental variables (rs1921622, rs55664618, rs62151861, rs2241116, rs1468790,
rs1523199 and rs56238602), then generated their effects on AD risk by the
association analysis in the Chinese_cohort_2 (WGS) dataset.
Mice. We housed all mice in the HKUST Animal and Plant Care Facility. All
animal experiments were approved by the HKUST Animal Ethics Committee
and conducted in accordance with the Guidelines of the Animal Care Facility of
HKUST. We housed four mice of the same sex in each cage at 22 °C and at a relative
humidity of 60%, with a 12-h light/dark cycle as well as food and water ad libitum.
WT C57BL6J mice were obtained from the Jackson Laboratory. The 5XFAD mice
were generated as previously described by overexpressing the p.Lys670Asn/p.
Met671Leu (Swedish), p.Ile716Val (Florida) and p.Val717Ile (London) mutations
in human APP as well as the p.Met146Leu and p.Leu286Val mutations in human
PSEN1 (ref. 100). We confirmed genotypes by PCR analysis of tail or ear biopsy
specimens. We performed all in vivo experiments on age-matched groups and
randomly assigned the mice to the experimental conditions. We chose our sample
sizes primarily based on our experience with similar types of experiments. We
conducted all animal experiments during the light phase.
In vivo experiments in mice. We delivered murine recombinant sST2-Fc (1004MR-050; R&D Systems) into 5XFAD mice (B6.Cg-Tg(APPSwFlLon,PSEN1*M
146L*L286V)6799Vas/Mmjax) via mini-osmotic pumps (model 1004; Alzet)
at 0.11 μl h−1. Specifically, we implanted the pumps intracerebroventricularly
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above the right hemisphere and loaded them with murine recombinant sST2-Fc
protein (240 ng per pump; 10 μg ml−1) or human IgG (as a control; 009-000-008;
Jackson ImmunoResearch) in artificial CSF (119 mM NaCl, 2.5 mM KCl, 2.5 mM
CaCl2·2H2O, 1 mM NaH2PO4·2H2O, 1.3 mM MgCl2·6H2O, 26.2 mM NaHCO3 and
11 mM d-glucose). After 28 d of administration, the mice were anesthetized with
isoflurane and transcardially perfused with PBS, and their brains were collected.
Immunohistochemical and immunofluorescence staining of mouse brains. The
left hemispheres of the mouse brains were fixed in 4% paraformaldehyde at 4 °C
for 24 h, transferred to 30% sucrose and stored at 4 °C until sectioning. We cut the
brains coronally into 50-μm sections with a vibrating blade microtome (VT1000S,
Leica) and stored them in cryoprotectant solution (30% glycerol, 30% ethylene
glycol and PBS) at −20 °C until use. For immunohistochemistry, we rinsed the
sections with PBST (that is, 0.1% Triton X-100 in PBS), then treated them with
formic acid at RT for 5 min for antigen retrieval, followed by 3% hydrogen peroxide
solution for 30 min to quench endogenous peroxidase activity. We blocked the
sections in 5% horse serum in PBST for 2 h, then labeled them with 4G8 antibody
(1:1,000 dilution; 800703, BioLegend) or D54D2 antibody (1:1,000 dilution;
8243S, CST) in blocking buffer overnight at 4 °C. The next day, we incubated the
sections with biotin-conjugated anti-mouse secondary antibodies (1:1,000 dilution;
BA2000, Vector Laboratories) followed by an avidin–biotin–HRP complex
(PK-6100, Vector Laboratories), and we developed signals with DAB kits (SK-4100,
Vector Laboratories or QD430-XAKE, BioGenex). Imaging was performed using a
Zeiss Axio Scan.Z1 Slide Scanner and processed in ZEN v3.3 (ZEISS). We analyzed
the Aβ plaque areas in cortical sections using the Analyze Particles function in Fiji
(ImageJ v1.53c). Specifically, we analyzed four brain sections from each mouse in
cortical regions (~200–300 μm apart) and calculated the average percentage of the
cortical area occupied by Aβ plaques.
For immunofluorescence analysis, we washed sections and incubated them
in 1 μM X-34 for 10 min. We then washed them in X-34 buffer (40% ethanol in
PBS), and then in PBS. We then blocked sections for 2 h in blocking buffer
(4% horse serum, 1% BSA and 0.3% Triton X-100 in PBS). Primary antibodies
used in experiments include mouse anti-Aβ (1:1,000 dilution; clone 4G8, 800703,
BioLegend), rabbit anti-Iba-1 (1:1,000 dilution; 019-19741, Wako) and rat
anti-Ki67 (1:200 dilution; clone SolA15, 14-5698-80, eBioscience); we diluted
these in blocking buffer and incubated sections overnight at 4 °C. Sections were
subsequently incubated with fluorophore-conjugated secondary antibodies
against mouse, rabbit and rat Ig (Alexa Fluor 488, 568 and 647; 1:1,000 dilution;
Life Technologies) in blocking buffer for 2 h at RT, extensively washed in PBST,
stained with SYTOX Green (1:300,000 dilution; S7020, Life Technologies) or DAPI
(1:5,000 dilution; D3571, Life Technologies) and mounted using FluorSave Reagent
(345789, Millipore).
We performed imaging using a Leica TCS SP8 confocal microscope with a Leica
×40 oil immersion objective. We took five images from each mouse cortex with a
step size of 1 μm for a total of 40 μm, then merged them into a single image with
maximum intensity z-projection. We identified three different plaque morphologies
using anti-Aβ immunolabeling (that is, 4G8) and X-34 staining: (i) filamentous
plaques characterized by filamentous X-34 and 4G8 labeling with no plaque core,
(ii) compact plaques characterized by 4G8 amyloid fibrils projecting radially
outward with an X-34–labeled core and (iii) inert plaques characterized by an X-34labeled core with no 4G8 labeling. We used a custom macro to segment individual
Aβ plaques and identified the type of each plaque manually. For plaque-associated
microglia, we counted the numbers of microglia surrounding small plaques (that
is, radius ≤ 8 μm) and large plaques (that is, radius > 8 μm) manually, as defined by
DAPI+ nucleus staining within the barrier surrounding the plaques and processes
in contact with the plaques. We defined the Ki67+ microglia as microglia with
Ki67 signals within the nucleus. To quantify microglial coverage of Aβ plaques,
we selected only compact plaques. We used ten optical slices 0.5 μm apart through
the center of the plaque for analysis. We processed all images with a customized
macro in Fiji (ImageJ v1.53c). On each slice, after adjusting the threshold, we
determined the perimeters of the plaque using the Analyse Particles and Area
to Line functions. We also determined plaque perimeters and the arcs of plaque
perimeters colocalized with microglial staining. We calculated the proportion of the
plaque perimeter covered by microglia by summing the arcs of the plaque perimeter
across three-dimensional (3D) stacks in close contact (within 1 μm) with Iba-1immunolabeled cells (~25 plaques per group). We conducted the 3D reconstruction
of microglia–plaque interaction using Imaris v9.7.2 (Oxford Instruments).
Assessment of microglial amyloid-beta phagocytic capacity. We examined
microglial Aβ phagocytic capacity as previously described25. Briefly, we injected
4-month-old 5XFAD or WT mice intraperitoneally with methoxy-X04 (10 mg
per kg body weight) to label the Aβ. We anesthetized the mice with isoflurane 3 h
after methoxy-X04 injection and perfused the left ventricle with ice-cold PBS. We
isolated, minced and incubated their forebrains at 37 °C for 30 min in 5 U ml−1
papain (LS003126) and 35 U ml−1 DNase I (LS002140; Worthington Biochemical)
for enzymatic digestion. After incubation, we depleted myelin debris by 30%
isotonic Percoll (P1644; Sigma-Aldrich) gradient centrifugation and obtained
mononuclear cell suspensions in DMEM/F12 medium with ice-cold 10% heatinactivated fetal bovine serum. We prepared unstained controls from mixtures
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of different sample cell suspensions for cell population identification. To label
microglia, we used an Alexa Fluor 488-conjugated mouse CD11b antibody (1:200
dilution; 53-0112-82; eBioscience) to stain the cell suspensions for 45 min at 4 °C.
We analyzed the resultant labeled cell suspensions using a BD Influx cell sorter
flow cytometer. We analyzed the recorded scatterplot data for the microglial cell
population using FlowJo software v10.5.0 (TreeStar).
Cell culture. The hCMEC/D3 cell line was purchased from Cedarlane and
cultured as previously described101. Briefly, we coated a tissue culture plate with
100 μg ml−1 type I collagen (Millipore) at 37 °C in 5% CO2 for 1 h. We subsequently
washed the plate with Dulbecco’s phosphate-buffered saline (DPBS) and replaced
it with a complete culture medium (endothelial cell growth medium-2 (Lonza)
supplemented with 5% fetal bovine serum (HyClone), 1% chemically defined lipid
concentrate (Gibco), 10 mM HEPES (Gibco), 5 μg ml−1 ascorbic acid (Sigma),
1.4 μM hydrocortisone (Sigma), 1 ng ml−1 basic fibroblast growth factor bFGF
(PeproTech), 10 U ml−1 penicillin and 10 μg ml−1 streptomycin (Gibco)). Cultured
cells were dissociated with 0.05% trypsin for 5 min, replated at 25,000 cells per
cm2 and returned to culture at 37 °C in a 5% CO2 incubator. Three to four days
after seeding, the cells reached confluence and could be passaged. We used cells at
passages 27–35 for our experiments.
For the ChIP–qPCR experiment, we fully changed the medium of the hCMEC/
D3 cells 2 h before treatment. We then treated cultured cells with recombinant
human IL-33 (BioLegend) or DPBS as a vehicle control for 24 h.
To evaluate the efficiency of the sgRNA editing in endothelial cells, we
transfected 5 × 105 hCMEC/D3 cells with a single CRISPR construct by
nucleofection using the Human Umbilical Vein Endothelial Cell Nucleofector
Kit (Lonza) with a Nucleofector 2b device (Lonza). One day after transfection,
we changed the cultured medium to a complete culture medium with 1 μg ml−1
puromycin (Thermo Fisher Scientific). After 3 d of puromycin selection, we
extracted genomic DNA using QuickExtract DNA Extraction Solution (Lucigen)
followed by a T7EI (NEB) editing efficiency test. All four sgRNAs exhibited high
editing efficiency (data not shown).
CRISPR/Cas9-mediated genome deletion of the rs1921622-harboring region.
To delete the region harboring rs1921622 in hCMEC/D3 cells, we used a dualguide, RNA-mediated knockout approach. The cells were genotyped from 300 bp
upstream and downstream of rs1921622 by Sanger sequencing. We performed
screening of potential Streptococcus pyogenes Cas9 (SpCas9)-guided RNAs using
the CRISPR design tool (https://crispr.mit.edu/) 100 bp upstream and
downstream of rs1921622. We used the following sgRNAs: sgRNA-1, 5′-TTATG
GACAGAATTAAGAAG-3′; sgRNA-2, 5′-CTGTCCATAAGATTTGAAAG-3′;
sgRNA-3, 5′-AATTTTGTTCTGGTAGCCAT-3′; and sgRNA-4, 5′-GGTAT
TTCAGCTAGTGCCTA-3′. We subcloned the sgRNAs into PX459v2, which
contains an sgRNA cassette, human codon-optimized SpCas9 and a puromycin
resistance gene.
To generate a dual-gRNA-mediated deletion cell line, we transfected the
hCMEC/D3 cells with plasmids containing sgRNA-1/sgRNA-4 (targeted 67-bp
deletion), sgRNA-2/sgRNA-3 (targeted 38-bp deletion) or PX459v2 as a no-sgRNA
control. After 3 d of puromycin selection (1 μg ml−1) starting from the day after
transfection, we seeded the puromycin-resistant cells in two 24-well plates. We
changed the culture medium twice a week. After 3 weeks, when a single colony was
observed, we passaged the wells containing only one colony into a 12-well plate.
We genotyped each clone and subjected those in which the targeted deletion may
have occurred to Sanger sequencing. This protocol generated six control lines,
eight lines with a 38-bp deletion and ten lines with a 67-bp deletion.
RNA extraction and real-time PCR. We extracted RNA using a NucleoSpin RNA
column (MACHEREY-NAGEL) according to the manufacturer’s instructions.
We first synthesized single-stranded cDNA using the PrimeScript RT Reagent
Kit (Takara Bio). We performed quantitative real-time PCR with TaqMan probes
(Thermo Fisher Scientific) and a Premix Ex Taq Kit (Takara Bio) using the 7500
Fast Real-Time PCR System (Applied Biosystems). The mRNA expression was
normalized to that of HPRT1.
Chromatin immunoprecipitation coupled to quantitative PCR. We modified
the ChIP–qPCR from the chromatin immunoprecipitation sequencing protocol
as previously described25. In brief, we trypsinized cultured cells and washed them
once with DPBS. Then, we immediately fixed 4 × 105 cells in suspension with 1.5%
paraformaldehyde at RT for 10 min and quenched them with 0.125 M glycine for
5 min. We subsequently centrifuged the cells at 500g for 5 min. We resuspended
the cell pellet in 0.25% SDS sonication buffer (10 mM Tris (pH 8.0), 0.25% SDS,
2 mM EDTA and protease inhibitors) and subjected it to sonication into 200–500bp fragments using the S220 Focused-ultrasonicator system (Covaris). We diluted
the DNA–protein mixture at a 1:1.5 ratio in equilibration buffer (10 mM Tris,
233 mM NaCl, 1.67% Triton X-100, 0.167% sodium-deoxycholate (Na-DOC),
1 mM EDTA and protease inhibitors). We spared 5% of the DNA–protein mixture
as input, while we incubated the remainder with antibodies against H3K4me3
(3 μl; 39159; Active Motif), H3K27ac (5 μl; 39133; Active Motif) or normal IgG
(6 μl; AB-105-C; R&D) overnight at 4 °C. Simultaneously, Protein A Dynabeads
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(Thermo Fisher Scientific) were washed twice and incubated with RIPA-LS buffer
(10 mM Tris-HCl (pH 8.0), 140 mM NaCl, 1 mM EDTA (pH 8.0), 0.1% SDS, 0.1%
Na-DOC, 1% Triton X-100 and protease inhibitors), then supplemented with 0.1%
BSA overnight at 4 °C. The next day, we added 10 μl pre-blocked beads to each
sample and incubated them for 2 h at 4 °C. We then washed protein-bound beads
twice with ice-cold RIPA-LS buffer, twice with ice-cold RIPA-HS buffer (10 mM
Tris-HCl (pH 8.0), 500 mM NaCl, 1 mM EDTA (pH 8.0), 0.1% SDS, 0.1% Na-DOC,
1% Triton X-100 and protease inhibitors), twice with ice-cold RIPA-LiCl buffer
(10 mM Tris-HCl (pH 8.0), 250 mM LiCl, 1 mM EDTA (pH 8.0), 0.5% NP-40, 0.5%
Na-DOC and protease inhibitors) and twice with ice-cold 10 mM Tris (pH 8.0)
buffer on a precooled magnetic stand. We then reverse-crosslinked the proteinbound and chromatin-bound beads with protease K (NEB) in ChIP elution buffer
(10 mM Tris-HCl (pH 8.0), 300 mM NaCl, 5 mM EDTA (pH 8.0) and 10% SDS)
at 55 °C for 1 h, then at 65 °C for 6 h. We diluted the input to a final concentration
of 0.4% SDS and 300 mM NaCl. Next, 2 μl protease K was added to the input and
incubated at 55 °C for 1 h, then at 65 °C for 6 h. We purified both the eluted ChIP
and input DNA with a MinElute column (Qiagen).
We performed real-time PCR for ChIP and input DNA using Power SYBR
Green Master Mix (Applied Biosystems) with the following primer pairs: sST2_
promoter_F, 5′-GGGAAAAAAGCTTGACTTTG-3′; sST2_promoter_R, 5′ATTTGACAAAGTTCACCCAG-3′; rs192_F, 5′-GCCACTTCTTAAT
TCTGTCC-3′; and rs192_R, 5′-GGTATTTCAGCTAGTGCCTA-3′.
Statistics and reproducibility. No statistical methods were used to predetermine
sample sizes, but our samples sizes are similar to those reported in previous
publications24,25,41,47. No data were excluded from the analyses, and the data
distribution was assumed to be normal, but this was not formally tested. We
assigned random codes to human samples before experiments and analyses;
and we randomly assigned nonhuman samples (for example, mice and cultured
cells) into experimental groups before experiments and sample collection. The
investigators were blinded to disease diagnosis and other demographic information
(for humans) and experimental groups and conditions (for mice and cultured cells)
during experiments.
For the remaining statistical analyses of human samples that are not mentioned
in the above methods, we conducted a linear regression analysis to determine the
significance of the associations between AD-associated endophenotypes (that is,
cognitive performance, brain region volume and AD biomarkers) and sST2 level
and/or rs1921622 genotype, adjusted for age, sex and other covariates as indicated
in the main text and figure legends. We obtained the CSF sST2 level cutoff based on
the CSF sST2 level with the maximum value of Youden’s index using the optimal.
cutpoints() function and the Youden method of the OptimalCutpoints package
(v1.1-4) in R102. We performed Cox regression to examine the association between
onset age of dementia and the rs1921622 A allele using the coxph() function of
the R survival package (v1.3-24), with sex and the top five principal components
as covariates. We tested the proportional hazard assumptions using the cox.zph()
function of the R survival package (v1.3-24; Supplementary Data 4). The level of
significance was set to P < 0.05 or FDR < 0.05. For data visualization, we used the
plot() function of R to generate a volcano plot and the ggplot() function of the R
ggplot2 package (v3.2.1) to generate dot plots. For the data obtained from mouse
and cell culture system experiments, we assessed the significance of differences
by unpaired Student’s t-tests, or one-way or two-way analysis of variance followed
by the Bonferroni post hoc test as indicated. The level of significance was set at
P < 0.05. We generated all statistical plots using Prism v8.0 (GraphPad).
Reporting summary. Further information on research design is available in the
Nature Research Reporting Summary linked to this article.

Data availability

Source data are available with this paper. All statistical data associated with
this study are contained in the main text, Supplementary Information or
Supplementary Data. All other data are available from the corresponding
author upon reasonable request. The consent forms signed by individuals from
Chinese_cohort_1 state that the research content will be kept private under
the supervision of the hospital and research team. Therefore, the phenotypic,
genomic and proteomic data of individuals will only be available and shared in
formal collaborations. A review panel hosted at HKUST will process and review
any applications for data sharing and project collaboration and promptly notify
applicants with the decision. Researchers may contact HKUST (sklneurosci@ust.
hk) for details about data sharing and project collaboration related to the present
study. The GRCh38/hg38 reference genome is available at https://hgdownload.
soe.ucsc.edu/downloads.html. The human frontal cortex snRNA-seq dataset
of the UKBBN cohort has been deposited in the Gene Expression Omnibus
(accession no. GSE157827). The genomic, demographic and clinical data of the
LOAD cohort are available on the National Institutes of Health (NIH) database of
Genotypes and Phenotypes (dbGaP) project (accession no. phs000168.v2.p2). The
genomic, demographic and clinical data of the ADC1–3 cohorts are available on
the NIH dbGaP project database (accession no. phs000372.v2.p1). The genomic,
demographic, clinical and brain imaging data of the ADNI cohort are available
at http://adni.loni.usc.edu/ upon request. The proteomic and demographic
629

Articles

NATuRE AGInG
26.

data from the INTERVAL and LonGenity cohorts are available at https://twcstanford.shinyapps.io/aging_plasma_proteome/. The genomic, demographic and
transcriptomic data from the GTEx cohort are available on the NIH dbGaP project
database (accession no. phs000424.v6.p1). The genomic, demographic, clinical
and brain imaging data of the AIBL cohort are available at https://aibl.csiro.au/
upon request.
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Extended Data Fig. 1 | Diagrams illustrating IL-33–ST2 signaling. (a) Schematic showing the soluble ST2 (sST2) and full-length ST2 (ST2L) transcripts.
(b) The IL-33/ST2 signaling pathways. IL-33, interleukin 33.
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Extended Data Fig. 2 | Associations between plasma soluble ST2 levels and Alzheimer’s disease in the Chinese_cohort_1, stratified by sex and
APOE-ε4 genotypes. (a) Individual plasma soluble ST2 (sST2) levels stratified by sex and disease phenotype (male: n = 132 healthy controls [HCs],
n = 84 individuals with Alzheimer’s disease [AD]; female: n = 204 HCs, n = 193 individuals with AD). Test for effects of sex: β = −3.848 and −3.257 in
HCs and individuals with AD, respectively; test for effects of AD: β = 1.926 and 2.235 in males and females, respectively. (b, c) Individual plasma sST2
levels stratified by APOE-ε4 genotypes and disease phenotype in (b) males (male ε4: n = 28 HCs, n = 29 individuals with AD; male non-ε4: n = 104 HCs,
n = 55 individuals with AD), and (c) females (female ε4: n = 25 HCs, n = 71 individuals with AD; female non-ε4: n = 179 HCs, n = 122 individuals with AD).
Test for effects of APOE-ε4: β = −1.809, −1.499, −0.248, and 2.425 in male HCs, male individuals with AD, female HCs, and female individuals with AD,
respectively; test for effects of AD: β = 2.034, 1.098, 3.833, and 1.811 in male ε4, male non-ε4, female ε4, and female non-ε4, respectively. ε4, APOE-ε4
carriers; non-ε4, APOE-ε4 noncarriers. Data are presented as box-and-whisker plots including maximum, 75th percentile, median, 25th percentile, and
minimum values; plus signs (+) denote corresponding mean values. Linear regression test, adjusted for age, cardiovascular disease status, body mass
index (BMI), and education level, with multiple testing correction; #FDR < 0.05, ##FDR < 0.01, ###FDR < 0.001; *FDR < 0.05, **FDR < 0.01, ***FDR < 0.001.
FDR, false discovery rate.
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Extended Data Fig. 3 | Associations between cerebrospinal fluid soluble ST2 levels and Alzheimer’s disease and amyloid-beta depositions in the
UKBBN cohort, stratified by sex. (a) Individual cerebrospinal fluid (CSF) soluble ST2 (sST2) levels stratified by sex and disease phenotype (n = 4 male
healthy controls [HCs], n = 36 male individuals with Alzheimer’s disease [AD], n = 7 female HCs, n = 39 female individuals with AD). Test for effects of
sex: β = −1.307 and −0.675 in HCs and individuals with AD, respectively; test for effects of AD: β = 4.019 and 7.766 in males and females, respectively.
Data are presented as box-and-whisker plots including maximum, 75th percentile, median, 25th percentile, and minimum values; plus signs (+) denote
corresponding mean values. Linear regression test, adjusted for age and postmortem duration (PMD), with multiple testing correction; *FDR < 0.05.
(b) Associations between amyloid-beta (Aβ) staining in the postmortem frontal cortex and CSF sST2 levels in male and female individuals with AD
(n = 23 males and 28 females in the UKBBN cohort, respectively). The regression lines and 95% confidence intervals are indicated in red/blue and
gray, respectively. Linear regression test, adjusted for age and PMD, with multiple testing correction. Test in males: β = 0.0256, Pearson’s r2 = 0.0024,
FDR = 0.7866; test in females: β = 0.2188, Pearson’s r2 = 0.1053, FDR = 0.0407. FDR, false discovery rate.
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Extended Data Fig. 4 | Effects of sex and age on soluble ST2 levels. (a) Individual plasma sST2 levels stratified by sex (n = 216 males, and 397 females
from Chinese_cohort_1). β = −3.577 for females vs. males, P = 1.58E − 12. (b) Associations between plasma sST2 levels and age in males and females
(n = 216 males, and 397 females from Chinese_cohort_1). Test in males: β = 0.0134, Pearson’s r2 = 0.0010, P = 0.8661; test in females: β = 0.1256, Pearson’s
r2 = 0.0366, P = 0.0016. (c) Correlations between plasma sST2 level and age in males and females from the INTERVAL and LonGenity cohort (n = 1,685
males, and 1,616 females from INTERVAL cohort; n = 432 males, and 530 females from LonGenity cohort). Test in INTERVAL cohort (ages 18–76),
males: Pearson’s r2 = 0.0169, P < 0.0001; females: Pearson’s r2 = 0.0001, P = 0.7715. Test in LonGenity cohort (ages 65–94), males: Pearson’s r2 = 0.0100,
P = 0.0093; females: Pearson’s r2 = 0.0196, P = 0.0001. (d) Correlations between CSF sST2 level and age in males and females from the Japanese cohort
(n = 68 males, n = 65 females). Test in males: Pearson’s r2 = 0.0441, P = 0.0812; test in females: Pearson’s r2 = 0.1521, P = 0.0014. (e, f) Contributions of age
and sex to the variance of sST2 levels. Numbers denote the proportions of plasma sST2 (e) and CSF sST2 (f) variance explained by age, sex, and other
factors in the Chinese_cohort_1 and Japanese cohort, respectively. Data in box-and-whisker plots are presented with maximum, 75th percentile, median,
25th percentile, and minimum values; plus signs (+) denote mean values; data in regression lines are presented as slope (red/blue) and 95% CIs (gray).
Statistical tests were performed by linear regression analysis, additionally adjusted for AD diagnosis, CVD status, BMI, education level in the Chinese_
cohort_1. *P < 0.05, **P < 0.01, ***P < 0.001.
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Extended Data Fig. 5 | The rs1921622 A allele is associated with better cognitive performance in female APOE-ε4 carriers in the AIBL Aβ+ cohort.
Individual cognitive scores in (a) overall Aβ+ APOE-ε4 carriers (n = 122 G carriers [G/-], n = 53 A/A carriers), (b) male Aβ+ APOE-ε4 carriers (n = 63 G
carriers [G/-], n = 24 A/A carriers), and (c) female Aβ+ APOE-ε4 carriers (n = 59 G carriers [G/-], n = 29 A/A carriers) stratified according to rs1921622
genotype. Test in the overall Aβ+ APOE-ε4 carriers, W = 3782.0, 3671.0, 3842.0, and 3319.0 for the effects of rs1921622 genotype on AIBL Preclinical
Alzheimer Cognitive Composite (AIBLPACC) score, attention processing score, episodic recall score, and recognition score, respectively; test in the male
Aβ+ APOE-ε4 carriers, W = 784.0, 727.0, 823.5, and 740.0 for the effects of rs1921622 genotype on AIBLPACC score, attention processing score, episodic
recall score, and recognition score, respectively; test in the female Aβ+ APOE-ε4 carriers, W = 1087.0, 1115.5, 1083.0, and 916.5 for the effects of rs1921622
genotype on AIBLPACC score, attention processing score, episodic recall score, and recognition score, respectively. Data in box-and-whisker plots are
presented with maximum, 75th percentile, median, 25th percentile, and minimum values; plus signs (+) denote mean values. Statistical tests are performed
by Wilcoxon rank-sum test, with multiple testing correction. *FDR < 0.05, **FDR < 0.01, ***FDR < 0.001. FDR, false discovery rate.
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Extended Data Fig. 6 | See next page for caption.
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Extended Data Fig. 6 | The rs1921622 A allele is associated with slower gray matter atrophy in female APOE-ε4 carriers in the AIBL Aβ+ cohort. (a, b)
Individual baseline (a: n = 128 G carriers [G/-], and 55 A/A carriers) and longitudinal gray matter volume (b: n = 148 datapoints from 37 G/- carriers, and
55 datapoints from 14 A/A carriers) in overall Aβ+ APOE-ε4 carriers stratified by rs1921622 genotype. Test on baseline data: W = 4109.0, FDR = 0.109. Test
on longitudinal data: β = −0.089 and −0.051 in G/- and A/A carriers, respectively; F = 3.830, FDR = 0.087. (c, d) Individual baseline (c: n = 64 G/- carriers,
and 24 A/A carriers) and longitudinal gray matter volume (d: n = 98 datapoints from 25 G/- carriers, and 36 datapoints from 9 A/A carriers) in male Aβ+
APOE-ε4 carriers stratified by rs1921622 genotype. Test on baseline data: W = 852.0, FDR = 0.434. Test on longitudinal data: β = −0.069 and −0.053
in G/- and A/A carriers, respectively; F = 0.272, FDR = 0.607. (e, f) Individual baseline (e: n = 64 G/- carriers, and 31 A/A carriers) and longitudinal gray
matter volume (f: n = 50 datapoints from 12 G/- carriers, and 19 datapoints from 5 A/A carriers) in female Aβ+ APOE-ε4 carriers stratified by rs1921622
genotype. Test on baseline data: W = 1240.0, FDR = 0.109. Test on longitudinal data: β = −0.159 and −0.027 in G/- and A/A carriers, respectively;
F = 8.804. Data in box-and-whisker plots are presented with maximum, 75th percentile, median, 25th percentile, and minimum values; plus signs (+)
denote mean values; data in regression lines are presented as slope (red/blue) and 95% confidence intervals (gray). Statistical tests on baseline data were
performed by Wilcoxon rank-sum test, with multiple testing correction; and statistical tests on longitudinal data were performed by linear mixed model
test, adjusted for baseline age and MRI scanners, with multiple testing correction. *FDR < 0.05, **FDR < 0.01, ***FDR < 0.001.
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Extended Data Fig. 7 | See next page for caption.
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Extended Data Fig. 7 | The rs1921622 A allele restores impaired microglial activities toward amyloid-beta in female APOE-ε4 carriers with Alzheimer’s
disease. (a, b) Representative images (a) and quantification (b) of Aβ plaques in the frontal cortices of individuals with AD stratified by sex and APOE-ε4
genotype (n = 14 male APOE-ε4 noncarriers [non-ε4], 22 male APOE-ε4 carriers [ε4], 19 female non-ε4, and 23 female ε4 from UKBBN cohort). Test for
sex: β = 2.871 (non-APOE-ε4) and 4.927 (APOE-ε4), P = 2.09E − 2 (non-ε4) and 4.61E − 5 (ε4); for APOE-ε4: β = −0.621 (males) and 1.967 (females),
P = 4.22E − 1 (males) and 4.84E − 2 (females). Scale bar, 200 μm. (c) Representative images of Aβ plaques in the frontal cortices of females with AD
stratified by APOE-ε4 and rs1921622 genotype. Scale bar, 5 mm. (d, e) Representative image (d) and quantification (e) of Aβ plaques (brown) and Iba-1+
microglia (purple) in the frontal cortices of individuals with AD stratified by sex and APOE-ε4 genotype (n = 14 male non-ε4, 22 male ε4, 19 female nonε4, and 23 female ε4). Test for sex: β = −1.214 (non-ε4) and −4.133 (ε4), P = 4.61E − 1 (non-ε4) and 3.52E − 4 (ε4); for APOE-ε4: β = −0.965 (males) and
−2.818 (females), P = 3.27E − 1 (males) and 6.00E − 3 (females). Scale bar, 100 μm. (f, g) Representative image (f) and quantification (g) of Aβ plaques
and microglia in the frontal cortices of females with AD stratified by APOE-ε4 and rs1921622 genotype (n = 4 G/G and 15 A/- carriers among non-ε4,
5 G/G carriers and 18 A/- carriers among ε4, respectively). Test for APOE-ε4: β = −3.745 (G/G) and −1.944 (A/-), P = 3.09E − 2 (G/G) and 9.32E − 2
(A/-); for rs1921622: β = 0.781 (non-ε4) and 2.017 (ε4), P = 7.70E − 1 (non-ε4) and 2.53E − 2 (ε4). Scale bar, 100 μm. Data in box-and-whisker plots
are presented with maximum, 75th percentile, median, 25th percentile, and minimum values; plus signs (+) denote mean values. Statistical tests were
performed by linear regression analysis, adjusted for age, PMD. *P < 0.05, **P < 0.01, ***P < 0.001; #P < 0.05, ##P < 0.01, ###P < 0.001.
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Extended Data Fig. 8 | The rs1921622 A allele and cerebrospinal fluid soluble ST2 level exhibit opposite effects on the microglial transcriptome in
female APOE-ε4 carriers with Alzheimer’s disease. Scatterplot showing the correlation between the normalized effect size (β) of cerebrospinal fluid (CSF)
soluble ST2 (sST2) levels and the rs1921622 A allele on microglial gene expression in the frontal cortices of female APOE-ε4 carriers with Alzheimer’s
disease (AD) (n = 2,636 microglia from 8 individuals from the UKBBN cohort).
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Extended Data Fig. 9 | Elevated brain soluble ST2 level exacerbates amyloid-beta deposition in female but not male 5XFAD mice. (a, b) Amyloid-beta
(Aβ) deposition in the cortices of 4-month-old male and female 5XFAD mice after 28-day intracerebroventricular delivery of soluble sST2 (sST2)-Fc or Fc
as a control. (a) Representative images of Aβ staining. Scale bar, 1 mm. (b) Quantification of Aβ plaques (% of total cortical area) (control: n = 6 male and
5 female mice, sST2: n = 6 male and 5 female mice). T = 0.590 (males) and 2.721 (females); P = 0.568 (males) and 0.026 (females). Data in bar charts are
mean + SEM. Statistical tests were performed as two-sided unpaired Student’s t-tests. *P < 0.05, **P < 0.01, ***P < 0.001.
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Extended Data Fig. 10 | Elevated brain soluble ST2 level leads to decreased amyloid-beta phagocytosis by microglia in female 5XFAD mice. (a, b)
Microglial amyloid-beta (Aβ) uptake activity in the cortices of 4-month-old female 5XFAD mice after 28-day intracerebroventricular delivery of soluble
ST2 (sST2)-Fc or Fc as a control. Representative distribution (a) and quantification (b) show the mean fluorescent intensity (MFI) of methoxy-X04labeled Aβ in the methoxy-X04+ CD11b+ microglia (control: n = 7 mice, sST2: n = 7 mice). T = − 2.490 and −2.014 for the tests in microglial with medium
Aβ uptake (MeX04MedCD11b+; left) and high Aβ uptake (MeX04HighCD11b+; right), respectively; P = 0.028 and 0.067, respectively. Data in bar charts are
mean + SEM. Statistical tests were performed as two-sided unpaired Student’s t-tests. *P < 0.05, **P < 0.01, ***P < 0.001.
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